Roche has unveiled a new ‘end-to-end’ pharma strategy which it believes will help deliver 20 transformative medicines over a ten year period.
Roche Aims To ‘Raise The Bar’ With New Wave Of Blockbusters
At an investor meeting in London, the Swiss company sets out plans for more disciplined decision-making to help it launch a new wave of blockbuster drugs.
More from Alimentary/Metabolic
More from Therapy Areas
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.